Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).
Protein tyrosine phosphatase 1B (PTP1B) inhibition has been recommended as a crucial strategy to enhance insulin sensitivity in various cells. PTP1B inhibitors improve the sensitivity of the insulin receptor and have the ability to cure insulin resistance-related diseases. In the latter years, targeting PTP1B inhibitors is being considered an attractive target to treat Type 2 diabetes and therefore libraries of PTP1B inhibitors are being suggested as potent antidiabetic drugs.
Prof. Hidayat Hussain and an international team of researchers published a review covering four years of published patents on potent PTP1B inhibitors as pharmaceutical agents to treat type 2 diabetes. New advancements suggest that it is possible to get small-molecule PTP1B inhibitors with the required potency and selectivity.
Reference:
Hidayat Hussain, Ivan R Green, Ghulam Abbas, Sergazy M Adekenov, Wahid Hussain and Iftikhar Ali. (2019) Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018). Expert Opinion on Therapeutic Patents. DOI: 10.1080/13543776.2019.1655542
